TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* English as the primary language~* Medically and psychologically suitable~* Willing to receive/have received meningitis / pneumococcal vaccinations~* Able to comply with study requirements, including travel to the investigational site~* Cochlear or retrocochlear anomaly/pathology that interferes with transmission of auditory information from the cochleae to the brainstem, resulting in severe to profound bilateral deafness (thresholds of 90 dB or worse in both ears on pure tone audiometry ranging from 250 to 2,000 Hz and speech recognition scores ≤ 30% in both ears). All subjects will undergo bone conduction audiometry and tympanometry to confirm sensorineural hearing loss and rule out potential middle ear disorders.~  * Conditions that cannot be otherwise treated, with conventional hearing aids or cochlear implants. If CI were previously used, subjects will have had a failed response, defined as ≤ 30% speech recognition and patient perception of inadequate benefit to continue using the device.~ * Expected subjects include those with these diagnoses:~    * Bilaterally severe/completely ossified cochleae~   * Bilateral cochlear malformations leading to poor CI outcomes~   * Bilateral temporal bone fractures, where the VIIIth cranial nerves have been disrupted~   * Bilateral cochlear nerve agenesis~   * Not a CI candidate based on above listed pathology, intolerable adverse effects with CI (e.g. stimulation of the facial nerve), or Evoked Auditory Potential testing predictive of a poor response~Exclusion Criteria:~* Anomalies/pathology involving the brainstem or cortex~* Retrocochlear pathology due to NF2 or other types of cranial nerve or brainstem neoplasm~* Co-existing medical conditions that require irradiation of the brainstem or auditory cortex~* Medical or psychological conditions that serve as contraindication to surgery~* Additional handicaps that would prevent or limit participation in evaluations~* Unrealistic patient or family expectations regarding the benefits, risks, and limitations inherent to the procedure and the prosthetic device~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-NF2 ABI surgery (Type: EXPERIMENTAL): All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Application of Magnetic Resonance Fat-Free Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant is capable of providing verbal consent.~* 18 years of age or older.~* Participants will belong to one of the following two categories:~* Patient with a known or suspected soft tissue sarcoma of the extremity or trunk who is/will be scheduled for an MRI scan as part of their routine care, -OR--~* Volunteer with no history of sarcoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pts/volunteers getting regular MRI exam (Type: None): Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Computed Tomography (CT) Scan Compared to Transesophageal Echocardiogram (TEE) in Endocarditis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Acute endocarditis with positive TEE~Exclusion Criteria:~* Renal failure~* Contrast dye allergy~* Beta-blocker allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 98 Years
- Healthy Volunteers: f

Study Arms:
- CT scan (Type: OTHER): CT Scan for endocarditis patients. All patients receive intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Presented to Regions Hospital ED for chief complaint of DKA, nausea, vomiting, abdominal pain, hyperglycemia, or similar~2. Meets all below diagnostic criteria for DKA per the American Diabetes Association:~   * Arterial or venous pH \</= 7.3~  * Serum Bicarbonate \</= 18 mEq/L~  * Ketonuria or ketonemia~  * Anion Gap \> 10~  * Blood sugar \> 250 mg/dL~3. Receiving IV insulin infusion~4. It is feasible to provide insulin glargine within 2 hours (+/- 30 minutes) of IV infusion start~5. Will be admitted to the ICU for DKA, or already admitted to the ICU for DKA~6. Ability to provide informed consent~Exclusion Criteria:~1. Age \< 18~2. End stage renal disease or hepatic disease~3. Hypotension requiring IV vasopressors or inotropes at any point during admission (i.e. norepinephrine, dobutamine, vasopressin, etc.)~4. Need for emergent surgery~5. Pregnant patients~6. Prisoners~7. Indication for insulin therapy other than DKA (hypertriglyceridemia, beta-blocker overdose, hyperglycemia without DKA)~8. Patients receiving prior to admission insulin pump therapy~9. Patients receiving prior to admission combination insulin products (i.e. Novolin® 70/30, Novolog® 70/30, Humalog® 75/25, etc.)~10. Did not consent to study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Subjects presenting to ED with diagnosis of DKA and receiving intravenous short acting insulin will not have orders for subcutaneous insulin glargine placed for research purposes.
- Intervention (Type: ACTIVE_COMPARATOR): Subjects presenting to ED with diagnosis of DKA will receive study medication set to begin within 2 hours after initiation of the IV insulin infusion. The dose will come from IV pharmacy and dispensed in a 1 mL insulin syringe. If the patient was not taking basal insulin prior to admission, the patient will receive 0.2 units/kg insulin glargine. If the patient was taking basal insulin prior to admission, the patient will receive their home insulin glargine dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Catheter Ablation Versus Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Permanent atrial fibrillation documented on at least 2 ecg´s with more than 1 month between ecg´s. The diagnosis is verified on Holter.~* All patients have symptoms or do not tolerate rate control treatment.~Exclusion Criteria:~* Psychiatric disease or suspicion of incapability to give informed concent~* Females with birth giving potential~* Previous heart surgery~* Previous ablation for atrial fibrillation~* Life expectance less than 1 year~* Congenital heart disease~* Expected need for heart surgery~* Heart failure (NYHA class IV)~* Inability to be treated with anticoagulation~* In case of previous deep venous thromboembolism og stroke the investigators will individually consider if the patient is suitable for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Patients with clinical suspicion of pancreatic head cancer who are scheduled to undergo surgical intervention with curative intent~* World Health Organization (WHO) performance score 0-2.~* Signed written informed consent~Exclusion Criteria:~* Medical or psychiatric conditions that compromise the patient's ability to give informed consent.~* Other invasive malignancy~* Pregnant or lactating women. Documentation of a negative pregnancy test must be available for woman of childbearing potential. Woman of childbearing potential are pre- menopausal women with intact reproductive organs and women less than two years after menopause.~* Prior neo-adjuvant chemo- of radiotherapy~* History of infusion reactions to bevacizumab or other monoclonal antibody therapies.~* Inadequately controlled hypertension with or without current antihypertensive medications~* Within 6 months prior to inclusion: myocardial infarction, Transient Ischemic Attack, Cerebral Vascular Accident, pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina pectoris.~* Anticoagulant therapy with vitamine K antagonists~* Patients receiving Class 1A (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents~* Evidence of QTc (corrected QT interval) prolongation on pretreatment ECG (greater than 44ms in males of greater than 450ms in females)~* Magnesium, potassium and calcium below the lower limit of normal range.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Bevacizumab-800CW

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntarily gives informed consent to participate in the study.~2. Right heart catheterization demonstrating conventional mean pulmonary artery pressure (mPAP) \>25, pulmonary vascular resistance (PVR) \>3.0 Wood Units, pulmonary capillary wedge pressure (PCWP) \<16 mmHg within two years of enrollment~3. Subject is 18 years of age or older at Screening.~4. Diagnosis of symptomatic idiopathic or heritable PAH, PAH associated with Connective Tissue Disease (CTD), PAH associated with repaired/unrepaired congenital systemic-to-pulmonary shunt, Portopulmonary hypertension or PAH associated with HIV infection.~5. New York Heart Association Functional Class II or III~6. Stable therapy with ambrisentan 5 or 10 mg every day for \> 90 days.~7. Baseline 6-Minute Walk Distance 50-450m~Exclusion Criteria:~1. Substantial Primary Lung disease~   * forced expiratory volume at one second (FEV-1)/forced vital capacity (FVC) \<0.6 and FEV-1 \<70% predicted~  * diffusing capacity of lung for carbon monoxide (DLCO) \<30% predicted~  * Pulmonary fibrosis~2. Left ventricular ejection fraction \< 50%~3. Pulmonary capillary wedge pressure \> 16 mm Hg~4. Aortic valve disease~5. Ischemic heart disease~6. Systemic hypotension (SBP \<90 mm Hg)~7. Co-existing treatment with other endothelin receptor antagonists or prostacyclin analogues~8. New York Heart Association Functional Class IV~9. Chronic thromboembolic pulmonary hypertension~10. Known or suspected pulmonary veno-occlusive disease~11. Serum creatinine \>2.0 mg/dL in women, Serum creatinine \>2.5 mg/dL in men~12. Baseline serum potassium \>5.0 milliequivalent (mEq)/L~13. Participation in ongoing drug/intervention-based clinical trial~14. Pregnancy~15. Unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMB + Spiro, Cardiopulmonary fitness (Type: ACTIVE_COMPARATOR): Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
- Placebo Cardiopulmonary fitness (Type: PLACEBO_COMPARATOR): Placebo mimics spironolactone 50 mg and will be taken QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Age \>= 18 years old.~* Metastatic breast cancer patients with lytic, sclerotic or mixed bone lesions.~* Non-symptomatic bone lesions, defined as pain absence, lack of bone complications (fracture, hypercalcemia, Central Nervous System (CNS) compression), no need of analgesic chronic administration for bone disease.~* A maximum of two chemotherapy lines for metastatic disease.~* A maximum of two hormone therapy lines for metastatic disease.~* Normal, minimally altered renal function (serum creatinine \< 1.5 x Upper Normal Limit (UNL)).~* Normal serum calcium levels.~* Performance status 0,1 (World Health Organization (WHO)).~* Negative pregnancy test before study recruitment.~Exclusion Criteria:~* Previous treatment with bisphosphonates or raloxifene in the 30 days prior to randomization.~* Metastasis in CNS.~* History of hypersensitivity to bisphosphonates.~* Pregnant or lactating women.~* Third chemotherapy line for metastatic disease.~* Third hormone therapy line for metastatic disease.~* Males.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Zoledronic acid 4 mg (Type: EXPERIMENTAL): Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
- Arm B: Observation (Type: NO_INTERVENTION): Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: I-Gel in Out-of-hospital Cardiac Arrest in Norway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Out-of-hospital cardiac arrest patients requiring and receiving advanced airway management on ambulance missions. Advanced airway management is defined as the attempted insertion of an airway adjunct (I-Gel, laryngeal tube or ETI) or the administration of ventilatory assistance/support (including bag-mask ventilation (BMV) or other ventilatory support.~* Adult patients (\> 18 years).~Exclusion Criteria:~* Non-adult patients / minors (\< 18 years).~* Traumatic cardiac arrest.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I-Gel (Type: ACTIVE_COMPARATOR): I-Gel supraglottic airway device
- LTS, ETI or other airway practice (Type: ACTIVE_COMPARATOR): Laryngeal tube, endotracheal tube or other current airway management practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major Depressive Disorder~* Current episode of major depression that has not benefited from at least 1 but no more than 3 adequate treatment regimens~* Has as score of \>/= 18 on the Ham-D-17~Exclusion Criteria:~* Pregnant or breast-feeding women~* Evidence of age-related cognitive decline or mild dementia~* At imminent risk of committing suicide~* Has with the exception of major depression, a serious medical or neurological illness, including seizure disorder, stroke, dementia, or Parkinson disease~* Has an established diagnosis of bipolar disorder, hypomania, schizoaffective disorder, major depression with psychotic features or schizophrenia~* Has had a substance or alcohol abuse or dependence disorder (except nicotine and caffeine) in the 1 year before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- EVT 101 (Type: EXPERIMENTAL): EVT 101

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are not doing other therapies for pain (physical therapy, chiropractic management, pool)~* Women between age 21 and 50 who plan to deliver at Loyola or Gottlieb~* Pain Numeric Rating Scale (NRS) on average of greater than or equal to 5/10 at Visit 1~* Pain must be between the upper level of the iliac crests and the gluteal folds in conjunction with or separately from pain in the pubic symphysis and influenced by position and locomotion~* 2/4 positive physical examination tests on the symptomatic side including the P4 test, the LDL test, pubic symphysis palpation and the acute straight leg rise (ASLR)~Exclusion Criteria:~* Women presenting with PGP in the first or third trimester (\<13 weeks gestation or \>28 weeks gestation)~* Women with pubic symphysis (anterior) pain alone~* Women who do not plan to deliver a baby at Loyola or Gottlieb~* Pain above the upper level of the iliac crest~* History of lumbar or pelvic fracture, neoplasm, inflammatory disease, active urogenital infection or active gastrointestinal illness, current physical therapy or other therapies for PGP, or previous surgery of the lumbar spine, pelvic girdle, hip joint or femur~* History or signs of radiculopathy or other systemic neurologic disease~* Women with diabetes or gestational diabetes

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
- Placebo (Type: PLACEBO_COMPARATOR): Participant's randomized to this condition will receive a placebo injection once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient (e) Age (e) over 18 years~* Kidney cancer metastatic or locally advanced~* Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together~* Proposed treatment in first line or second line~* Brain imaging not finding brain metastases~* Having signed the informed consent of study participation~* The patient may have received prior anti-angiogenic~Exclusion Criteria:~* Cancer of the kidney other than primitive~* Previous history of cancer other than kidney cancer in complete remission for less than 5 years~* Patients under 18 years~* Patients whose treatment is associated with chemotherapy~* disorders of cognitive functions to existing treatment delivery~* Pathology psychiatric evolutionary~* Refusal of participation~* Patient unable to respond to cognitive tests~* Drug use~* Heavy drinking (WHO criteria)~* History of stroke~* History of head trauma~* Brain metastases known~* MMS below normal compared to existing standards for age and socio-cultural

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients group (Type: None): Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues